Evidence map›Paper›PMID 41745172›Full record

ArticleNanomaterials (Basel, Switzerland)2026

Treatment of Maxillofacial Cancers by Zein Nanoparticles Loaded with Anticancer Peptide Pistacia Zardin1: Enhanced Cytotoxicity and Apoptosis Induction in Head and Neck Squamous Cell Carcinoma (HNSCC).

Andrej Jenča, Elham Saberian, Janka Jenčová, Adriána Petrášová, Andrej Jenča, David Mills, Hadi Zare-Zardini, Eliška Kubíková, Simona Dianišková, Tetyana Pyndus

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andrej JenčaAcademy of Košice, Pavol Jozef Šafárik University, Solmea s.r.o., Bačíkova 7, 04001 Košice, Slovakia.
Elham SaberianAcademy of Košice, Pavol Jozef Šafárik University, Solmea s.r.o., Bačíkova 7, 04001 Košice, Slovakia.ORCID 0000-0002-0590-9489
Janka JenčováSpecialized Hospital Head and Neck Diseases, Academy of Košice, Pavol Jozef Šafárik University, Solmea s.r.o., Bačíkova 7, 04001 Košice, Slovakia.
Adriána PetrášováAcademy of Košice, Pavol Jozef Šafárik University, Solmea s.r.o., Bačíkova 7, 04001 Košice, Slovakia.
Andrej JenčaAcademy of Košice, Pavol Jozef Šafárik University, Solmea s.r.o., Bačíkova 7, 04001 Košice, Slovakia.ORCID 0000-0003-4501-7407
David MillsMolecular Science and Nanotechnology, College of Engineering and Science, Louisiana Tech University, Ruston, LA 71272, USA.ORCID 0000-0002-6489-4520
Hadi Zare-ZardiniDepartment of Biomedical Engineering, Meybod University, Meybod 896169557, Iran.ORCID 0000-0002-1501-2560
Eliška KubíkováFaculty of Medicine, Department of Anatomy, Comenius University, 81108 Bratislava, Slovakia.
Simona DianiškováDepartment of Dentistry, Slovak Medical University, 81108 Bratislava, Slovakia.ORCID 0009-0006-3375-7992
Tetyana PyndusDepartment of Dentistry, Pavol Jozef Šafárik University, Solmea s.r.o., Bačíkova 7, 04001 Košice, Slovakia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinomas (HNSCCs) are considered the most common histological type of head and neck cancer. This study aims to develop a drug delivery system based on zein protein nanoparticles (Zein NPs) to enhance the therapeutic effect of the anticancer peptide, Pistacia zardin1 (PZ1), for the treatment of maxillofacial cancers. PZ1-Zein NPs were synthesized by the desolvation method. These spherical nanoparticles (size: 162.8 nm, PDI: 0.27) showed high encapsulation efficiency (89%) and pH-responsive release (with higher drug release in the acidic tumor microenvironment). In vitro cytotoxicity assays showed that PZ1-Zein NPs significantly reduced IC50 values in HNSCC cell lines (e.g., SCC-25: 7.5 µM vs. 19.3 µM for free peptide,

Indexed as

apoptosisdrug deliveryhead and neck squamous cell carcinoma (HNSCC)maxillofacial cancerPistacia zardin1zein nanoparticles

Identifiers

PMID41745172
PMCPMC12942940

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.